Skip to Content

Press Releases

Press Releases

Nov 05 2015
Intec Pharma Reports Results for the Third Quarter of 2015
JERUSALEM, ISRAEL--(Marketwired - Nov 5, 2015) -   Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTP) ("Intec Pharma" or the "Company"), an Israeli clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced its
Oct 22 2015
Intec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe
JERUSALEM, ISRAEL--(Marketwired - Oct 22, 2015) -  Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the Company has been informed by the European
Oct 12 2015
Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms
JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) -  Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study of the Phase 3
Sep 17 2015
Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares
JERUSALEM, ISRAEL--(Marketwired - Sep 17, 2015) -  Intec Pharma Ltd . (the "Company") (NASDAQ: NTEC) (TASE: INTC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the underwriters of its
Displaying 71 - 74 of 74